Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated